WVE News and Press, Wave Life Sciences Ltd. From 06/14/22

Wave Life Sciences (NASDAQ:WVE) priced an underwritten offering of 25.5M shares at an offering price of $2.15/share and to RA Capital Management, in lieu of ordinary shares, pre-funded warrants to purchase up to 7.09M shares. The per share offering price for the ordinary shares represent...

CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the ...

CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Execu...

Then shares of Wave Life Sciences (NASDAQ:WVE) are trading lower in the morning hours Friday after H.C. Wainwright trimmed the price target for the clinical-stage genetic medicine company citing a lack of clarity on its clinical front in the near term. As the company plans to share results fo...

Gainers: Inotiv (NOTV) +41%. TScan Therapeutics (TCRX) +23%. SomaLogic (SLGC) +19%. Veru (VERU) +18%. Celularity (CELU) +17%. Losers: Opiant Pharmaceuticals (OPNT) -16%. Renovacor (RCOR) -15%. Embecta (EMBC) -7%. Wave Life Sciences (WVE) -5%. ...

The following slide deck was published by Wave Life Sciences Ltd. in conjunction with their 2022 Q1 earnings call. For further details see: Wave Life Sciences Ltd. 2022 Q1 - Results - Earnings Call Presentation

Wave Life Sciences Ltd. (WVE) Q1 2022 Earnings Conference Call May 12, 2022, 8:30 AM ET Company Participants Kate Rausch - Head, Investor Relations Paul Bolno - President and Chief Executive Officer Mike Panzara - Chief Medical Officer, Head, Therapeutics Discovery and Development Kyle Moran ...

Wave Life Sciences press release (NASDAQ:WVE): Q1 GAAP EPS of -$0.62 misses by $0.06. Revenue of $1.75M (+17400.0% Y/Y) misses by $2.11M. As of March 31, 2022, Wave had $111.7 million in cash, cash equivalents and short-term investments. As of December 31, 2021, Wave had $...

Delivered first clinical data demonstrating target engagement and translation of PN chemistry’s impact in clinic; Adapting ongoing Phase 1b/2a FOCUS-C9 clinical trial to optimize dose level and frequency, with additional single and multidose data expected throughout 2022 ...

Wave Life Sciences (NASDAQ:WVE) Q1 consensus EPS estimate is -$0.55 and consensus revenue estimate is $3.86M. WVE is scheduled to announce Q1 earnings results on Thursday, May 12, before market open. Over the last 3 months, EPS estimates have seen 4 upward revisions and 0 downw...